DNAnexus Completes $68 Million Financing

Financing to support expansion in translational informatics and drive
adoption of DNAnexus Apollo™, a powerful new platform to advance drug
discovery and improve clinical outcomes

, the leader in biomedical informatics and data management,
today announced closing a $68 million financing. The funds were raised
from existing investors, GV (formerly Google Ventures), Foresite
Capital, TPG Biotech, WuXi NextCODE, and Claremont Creek Ventures, as
well as debt and equity financing from Innovatus Capital Partners, LLC.

“DNAnexus has changed how global biomedical research and development
markets manage their data and infrastructures,” commented Claes Ekstrom,
Managing Director at Innovatus. “We are excited to support DNAnexus’
ongoing mission to accelerate science and medical discoveries by
democratizing access to data through a global network.”

The financing supports the deployment of DNAnexus
™, an advanced platform for multi-omics and clinical data
exploration, analysis, and discovery. The Apollo Platform uses the
DNAnexus global network, providing secure and compliant infrastructure
with access to tools and datasets within a collaborative environment.
DNAnexus supports some of the largest human genome sequencing projects
in the world, including NIH’s
All of Us
, St.
Jude Cloud
, AstraZeneca’s
2-million genome initiative
, and the Regeneron-Geisinger

“The financing enables further development of our translational research
solutions, as well as continued growth in genomics with cloud-based
solutions for research, clinical diagnostics, and clinical trials,” said
Richard Daly, Chief Executive Officer at DNAnexus. “The next wave of
biomedical insights will be derived from cross-institutional
collaborations that generate massive volumes of clinical and multi-omics
data. We are proud of our work dedicated to improving how global
research and development organizations leverage large biomedical
datasets to develop and deliver precision medicine solutions.”

About DNAnexus

DNAnexus, the leader in biomedical informatics and data management, has
created the global network for genomics and other biomedical data,
operating in 33 countries including North America, Europe, China,
Australia, South America, and Africa. The secure, scalable, and
collaborative DNAnexus Platform helps thousands of researchers across a
spectrum of industries – biopharmaceutical, bioagricultural, sequencing
services, clinical diagnostics, government, and research consortia –
accelerate their genomics programs. For more information on DNAnexus,
please visit www.dnanexus.com
or follow the company @DNAnexus.

About Innovatus Capital Partners

Innovatus adheres to an investment strategy that identifies disruptive
and growth opportunities across multiple asset categories with a
unifying theme of capital preservation, income generation, and upside
optionality. The Firm has a dedicated team of life sciences investment
professionals with deep experience in healthcare, including life
sciences. Innovatus and its principals have significant experience
providing debt financing to medical device, diagnostics, and
biotechnology companies that address unmet medical needs, improve
patient outcomes, and reduce overall healthcare expenditures. Further
information can be found at innovatuscp.com.


Media Contact:
CG Life for DNAnexus
Mark Button,

Alyssa Salela, 630-935-6369

error: Content is protected !!